BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24462773)

  • 1. CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells.
    Tsai HC; Huang CY; Su HL; Tang CH
    Biochim Biophys Acta; 2014 May; 1843(5):846-54. PubMed ID: 24462773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
    Tsai HC; Huang CY; Su HL; Tang CH
    PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1.
    Wang MY; Chen PS; Prakash E; Hsu HC; Huang HY; Lin MT; Chang KJ; Kuo ML
    Cancer Res; 2009 Apr; 69(8):3482-91. PubMed ID: 19351859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S; Huang X; Lee CK; Liu B
    Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
    Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
    J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.
    Zhang M; Mukherjee N; Bermudez RS; Latham DE; Delaney MA; Zietman AL; Shipley WU; Chakravarti A
    Prostate; 2005 Aug; 64(3):293-302. PubMed ID: 15754318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
    Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
    Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
    Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
    Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survivin siRNA increases sensitivity of primary cultures of ovarian cancer cells to paclitaxel.
    Kar R; Palanichamy JK; Banerjee A; Chattopadhyay P; Jain SK; Singh N
    Clin Transl Oncol; 2015 Sep; 17(9):737-42. PubMed ID: 26033427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.
    Liu H; Tekle C; Chen YW; Kristian A; Zhao Y; Zhou M; Liu Z; Ding Y; Wang B; Mælandsmo GM; Nesland JM; Fodstad O; Tan M
    Mol Cancer Ther; 2011 Jun; 10(6):960-71. PubMed ID: 21518725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].
    Yan XJ; Liang LZ; Zeng ZY; Shi Z; Fu LW
    Ai Zheng; 2006 Apr; 25(4):398-403. PubMed ID: 16613669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-κB pathway.
    Lin CL; Chen RF; Chen JY; Chu YC; Wang HM; Chou HL; Chang WC; Fong Y; Chang WT; Wu CY; Chiu CC
    Int J Mol Sci; 2012; 13(5):6236-6245. PubMed ID: 22754361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma.
    Shimbo A; Kajiyama H; Tamauchi S; Yoshikawa N; Ikeda Y; Nishino K; Suzuki S; Niimi K; Sakata J; Kikkawa F
    Oncol Rep; 2019 Dec; 42(6):2323-2332. PubMed ID: 31578579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine.
    Yang Y; Niu X; Zhang Q; Hao L; Ding Y; Xu H
    Am J Med Sci; 2012 Sep; 344(3):199-205. PubMed ID: 22222334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
    Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
    Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
    Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
    Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines.
    Ho TF; Peng YT; Chuang SM; Lin SC; Feng BL; Lu CH; Yu WJ; Chang JS; Chang CC
    Toxicol Appl Pharmacol; 2009 Mar; 235(2):253-60. PubMed ID: 19133282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel.
    Togashi K; Okada M; Yamamoto M; Suzuki S; Sanomachi T; Seino S; Yamashita H; Kitanaka C
    Anticancer Res; 2018 Aug; 38(8):4535-4542. PubMed ID: 30061219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.